{"title":"Purified Cucurbitacin D Leads to Alterations of Apoptotic and Autophagic Genes Expression in MDA-MB-468 and MCF-7 Human Breast Cancer Cells.","authors":"Elham Zeinali, Seyed Jalal Zargar, Najmeh Mozdoori","doi":"10.1111/ajco.70009","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The use of plant-derived drugs in cancer therapy is widely considered in the treatment of different malignancies including breast cancer. Cucurbitacin D (CuD) is able to induce apoptosis in cancerous cells through different signaling pathways. The aim of this study was to examine the effect of different concentrations of CuD on viability and death pattern.</p><p><strong>Methods: </strong>Antiproliferative effects of CuD on these cell lines' viability were investigated using the MTT assay. Real-time PCR was applied to evaluate the expression alterations of Bcl-2, Bax, caspase-3, p53 (that related to apoptotic cell death pathway), Atg5, Beclin-1, PTEN, and Akt genes (autophagy genes) in the MCF-7 (ER positive) and MDA-MB-468 (triple negative) breast cancer cells.</p><p><strong>Results: </strong>Significant dose-dependent and antiproliferative effects of CuD were observed on MCF-7 and MDA-MB-468 cells after 24 h with IC50 value about 30 and 25 µM, respectively (p < 0.01). Significant changes in expression of the genes in the breast cancer lines were observed under different concentrations of CuD.</p><p><strong>Conclusion: </strong>Our results confirmed that CuD may influence breast cancer cell lines' viability at specific doses and by altering the expression of these genes. The differences between the gene's aberrations in our breast cancer cell lines propose that these genes can have a distinct role in the pathophysiology and therapy responsiveness of various subtypes of breast cancer.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.70009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: The use of plant-derived drugs in cancer therapy is widely considered in the treatment of different malignancies including breast cancer. Cucurbitacin D (CuD) is able to induce apoptosis in cancerous cells through different signaling pathways. The aim of this study was to examine the effect of different concentrations of CuD on viability and death pattern.
Methods: Antiproliferative effects of CuD on these cell lines' viability were investigated using the MTT assay. Real-time PCR was applied to evaluate the expression alterations of Bcl-2, Bax, caspase-3, p53 (that related to apoptotic cell death pathway), Atg5, Beclin-1, PTEN, and Akt genes (autophagy genes) in the MCF-7 (ER positive) and MDA-MB-468 (triple negative) breast cancer cells.
Results: Significant dose-dependent and antiproliferative effects of CuD were observed on MCF-7 and MDA-MB-468 cells after 24 h with IC50 value about 30 and 25 µM, respectively (p < 0.01). Significant changes in expression of the genes in the breast cancer lines were observed under different concentrations of CuD.
Conclusion: Our results confirmed that CuD may influence breast cancer cell lines' viability at specific doses and by altering the expression of these genes. The differences between the gene's aberrations in our breast cancer cell lines propose that these genes can have a distinct role in the pathophysiology and therapy responsiveness of various subtypes of breast cancer.
期刊介绍:
Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.